Get Elivated

About the offering

We founded Elivate to change how people approach and engage in the second half of their lives. We built our model on 3 key inputs: the breakthroughs emerging from aging & longevity science, the size and success of the existing home infusion therapy market, and the preferences and behavior of our customers since we launched in Nov 2023. We also deliver home infusion & injection therapies - focused completely on treatments that can improve healthspan. Our market is $25B now & projected to be $44B by 2030. Elivate delivers Longevity & Anti-senescence therapies focused on extending healthspan at a cellular level (Source). Projected $126B 2029 GLP-1 sales (Source) “Longevity’s first blockbuster drug” (Source): GLP-1s like Ozempic are highlighting the potential of future emerging therapies that Elivate intends to deliver. 32% increase in consumer adoption over 10 years. Consumers in the adoption phase of longevity tracking and treatments are projected to rise from 8% to 40% over the next 10 years (aligned with typical technology adoption curves and the projected growth of the US longevity market)(Source, Source). THE PITCH The Future of Aging Is Changing – What Does That Mean For You? "Science is showing that while chronological aging is inevitable, biological aging is malleable. There's a part of it that you can fight, and we are getting closer and closer to winning that fight." — Eric Verdin, MD, CEO., Buck Institute Eric Verdin is not affiliated with the Company and his statement does not constitute an endorsement of the Company or this offering. We’ve all grown up with expectations that aging will cause decline, and we’re uncertain when and what we will have to deal with as we age. Unfortunately, our fears too often become reality. The number of years we live (“lifespan”) has jumped from 47 to 73 since 1950 (Source). That sounds like a huge opportunity, but the potential is constrained, mainly because of chronic disease (Source). Living longer doesn’t mean living better. The years we live healthy, active, and free from diseases or disabilities are called our “healthspan”. Think of healthspan as the years spent doing the things you love—like playing with grandkids, traveling, or pursuing new things—without being held back by chronic illness or pain. The problem is that there’s a growing gap between our lifespan and our healthspan. Over the past two decades, that gap in the US increased from 10.9 to 12.4 years, resulting in a 20% higher gap than the global mean. This means Americans spend an average of 12.4 years at the end of their lives with significant illness or disability (Source). We now have the power to change our aging story – to close the gap between lifespan and healthspan. By optimizing today, you may be able to live 15 to 20 years longer in good health, doing more of what you love without being held back by chronic illness or pain.* For most of us in the US, the average life expectancy is 75. 95 should be your goal for everyone (Source 39:45). *Individual results may vary and are not guaranteed. We believe we have the power to increase the proportion of years spent in good health from 85% to allow many Americans potentially living up to 95% of their years in good health and live to be nearly 90 years old (Source). *Individual results may vary and are not guaranteed. We have engineered Elivate’s business model to optimize a specific objective that will have growing importance in the longevity industry: accelerating consumer adoption. These longevity & anti-senescence therapies have the potential to significantly improve healthspan – IF people use these therapies. This kind of behavior change is hard for humans, and great therapies aren’t enough to drive it. We have the experience to bridge the gap between the amazing research, development, and therapies emerging in longevity. That enabled us to custom-build, implement, and achieve PMF in year one with a delivery and per-unit economic model that optimizes adoption. Read on to learn about both our initial “healthspan housecall” model and our growth strategy to expand channels and offerings to drive our next phase of revenue growth and scale. *Expansion plans are based on management’s current expectations and are subject to change. We intend to evolve Elivate to encourage behavior change and support improved quality of life results for as many people as possible. We are committed to working to improve healthspan because we believe it’s the defining opportunity of our lifetime. Join us to enable as many people as possible to achieve more years of feeling good, being independent, and having a higher quality of life. THE MARKET Focus on healthspan improvement Unfortunately, living longer doesn't mean living better. We're all facing years of diminished quality of life, mainly because of chronic disease. -The number of Americans aged 50+ are projected to increase from 137.25M in 2020 to 221.13M in 2050 (61.11%) (Source). -The number of Americans aged 50+ expected to battle chronic disease is estimated to increase by 99.5% 2050 (Source). -Chronic diseases are responsible for 71% of annual deaths globally, and 79% of all years lived with disability (Source). Using a proven model: More emerging therapies require infusion or injection, 47% of drugs approved by the FDA since the start of 2021 require infusion or injection (Source). Conditions like cancer and cardiovascular disease increasingly require long-term infusion treatments that can be delivered effectively at home (Source, Source). Personalized care delivered at home by licensed nurses reduces hospital stays, lowers healthcare costs, and improves adherence to treatment protocols (Source, Source). Applied to preventative longevity treatments to improve healthspan Traditional medicine focuses on treating individual chronic diseases as they arise. Anti-senescence therapies are one of the components that address aging itself. Instead of managing diabetes, cardiovascular disease, or neurodegeneration separately, these therapies aim to prevent or delay their onset by rejuvenating cellular function (Source, Source). These therapies offer the potential to significantly improve outcomes. The treatments and services offered by Elivate are not FDA-approved, and some referenced therapies are experimental or in development. Information provided is for educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Biological age diagnostics We plan to measure healthspan improvement using leading aging metrics, based on the science behind them and consumer insight. When people see their biological age for the first time, it's really powerful - it seems to be the leading emotional "spark" that prompts initial adoption in the longevity category. We believe measuring progress with aging or similar metrics will accelerate consumer adoption of longevity practices and treatments significantly. Actual data: Elivate's founder and CEO is 16 years biologically younger than her chronological age. In one 6-month period using supplements and nutrient infusions, she lowered her biological age by 3 years.* *This example is based on internal data and individual experience; actual results may differ. OUR SOLUTION Longevity-as-a-Service focused on healthspan improvements We believe Elivate is one of the first movers in the $25 billion longevity & anti-senescence therapies market (Source), not by developing these therapies but by focusing on delivering them to consumers directly and for our partners. Customer Experience We focus on getting longevity treatments into people's bodies - where they are, when it's convenient for them, and in a comfortable, familiar environment - at home. We flipped the infusion business model on its head to build a better experience: Healthspan Housecalls. Lower barriers to entry Meet customers where they are: People don't yet know enough about preventative health or longevity treatments to choose an infusion or injection as their first step - so we don't ask them to. Focus on the familiar: We shifted the focus from buying to reserving - requesting a time is a 1-click conversion Reframe the offering: Make the housecall the product not the infusion Curate the visit Don't prioritize price: To confirm a time reservation, we require a $200 deposit with no impact on conversion Process = opportunity: Turn hassle into opportunity to educate, engage while working through the process Customize & curate: We deliver the services the customer wants, we enable individual payments, we bring Bloody Mary bars - it's personal Plan to maximize value: 45 to 60 mins of undivided attention > 7 yearly minutes with a doctor Collaboration fosters trust and revenue: Advisor/customer collaboration on the visit plan > early engagement & trust Deliver the whole experience Maximize comfort and convenience: 70% prefer to receive health care at home Empower them: Help them learn the science and fight through the noise to make their own decisions Create a dialogue: Make the time & attention matter so the functional & emotional value is equal Curiosity creates credibility: learn about their needs, their family's needs, their healthspan goals, their past experiences Understand how they define success to enhance the attention, guidance, and longevity education Celebrate the imbalance between level of care and mass-market access Elivate's model is similar - but focused on preventative health, specifically longevity treatment delivery. We believe we are among the first companies focused exclusively on delivering a comprehensive suite of longevity and anti-senescence therapies directly to people in their homes in the same way that home health agencies deliver care. Elivate's Longevity-as-a-Service model is committed to its goal of making longevity treatments affordable and accessible to the majority. Our customers so far include both people who want to prevent chronic disease and those managing chronic disease. THE OPPORTUNITY Elivate aims to give people affordable access to cutting-edge longevity treatments as a service. Our nurse providers deliver infusion & injection therapies - specifically targeting anti-aging, healthspan extension, or cellular rejuvenation - in home to help people improve healthspan over time. We are working to define a new category in preventative healthcare - home-delivered longevity treatments via infusion & injection - by leveraging our existing customer base, nurse network, and operational model. Business model We developed Elivate's business model based on: Our first customers preferences, feedback, and behavior. Analysis of cost to acquire a customer across our delivery channel testing. The current home infusion therapy market We were able to create a differentiated model that achieves win-win between customer value and profitability by remixing four proven elements: In-home healthcare, Licensed nurse providers, Infusions & injections, Longevity-focused treatments All four of the components are familiar - but we believe we are one of the few companies focused exclusively on delivering longevity and anti-senescence therapies via infusion & injection directly to people in their homes in the same way that home health agencies deliver traditional care. Growth in consumer adoption Delivering these treatments to improve healthspan is not enough. We believe we can help companies across the longevity industry grow. We also developed our model based on our expertise in consumer perceptions & behavior. Initial results appear effective at accelerating longevity adoption. This consumer superpower is what we bring to the longevity industry, and we hope to apply it to ensure the innovations of scientists and doctors have as much impact as possible. Human opportunity Recent research showed that 87% of Americans want to take steps to live healthier for longer, with 53% aspiring to reach the age of 100 or beyond (Source). We believe that's within our power, and it will take a big shift in mindset. What if, instead of fearing aging, we could embrace it as an opportunity for growth & purpose? We are excited to play a part in helping to transform the aging experience from one of fear & limitation to one of possibility and growth. Managing how we age can dramatically change what the second half of our lives means for us, for our families, and for society overall. We believe proactive aging has the potential to reshape our culture - as more people take control of how they age, we could see a surge in social engagement, intergenerational connections, and the application of hard-earned wisdom to solve complex societal issues. Economic opportunity Improving healthspan also has significant economic implications. Contrary to the myth that older people are a drain on our systems, people 50+ contribute massively to our economy and benefit society and Americans of all ages (Source). One study estimated that delaying aging by just one year could add $38 trillion in economic value globally. Extending healthspan by ten years could potentially generate $367T in global economic value (Source). It is projected that by 2050, when Gen Zers will be turning 50, the 50-plus age group will contribute $26.8T to the U.S. economy (Source). TRACTION The first phase of growth for Elivate's longevity-as-a-service model focused on customer immersion to learn about the target market, positioning, key messages, obstacles, and more through thousands of in-person consumer interactions and close to 1000 services delivered. We also tested target markets, delivery service models, and treatment perceptions and efficacy. Momentum in our first growth phase has been driven by our primary path to consumer adoption - booking a nutrient infusion or injection. Highlights of traction across core audiences: CONSUMERS: Concept to service delivery in 141 days - in the most medically-regulated state in the US, Analyzed KPIs across all down to the CPA per event level, Identified the most effective & profitable model and fully focused on that one delivery model, Custom-built the healthspan housecall model, CX, economics, Built infrastructure to enable the chosen business model, $255 ARPU, 1/3 repeat customers, 47% of revenue from repeat customers, 3 to 4x lower labor & marketing costs/housecall (average 3 to 4 customers per nurse hour), Customer advocacy and referrals, $79,800 revenue, Customer lifetime value >$1500, Labor costs down 77%, COGS down 45%, Installation at The Village at Palisades Tahoe PARTNERS: Identified differentiators vs. upstream brands and created last-mile delivery offering, Identified B2B channel to add revenue stream, Validated demand for last-mile delivery INDUSTRY: Defined the market sector we are targeting, Identified consumer adoption gap, Developed unique positioning and POV to match our superpowers with market white space Past performance and historical results are not guarantees of future outcomes or success. GROWTH PLAN These growth plans are based on management's current expectations and are subject to risks and uncertainties. We aim to scale using a dual strategy: Direct-to-Consumer (DTC) home-based longevity therapies and Business-to-Business (B2B) delivery partnerships with multiple categories of longevity companies. The convergence of market trends-rising chronic disease prevalence, the growing lifespan-healthspan gap, increasing demand for infusion-based therapies, and consumer preference for home-based care-combined with learning and traction from our first 18 months - we feel has positioned us for potential growth. To best take advantage of these market tailwinds, we plan to leverage these drivers of growth: CONSUMERS: Additional treatment categories, Leverage unit economics to increase revenue and scale, Increase in longevity adoption PARTNERS: B2B partnerships to deliver Longevity-as-a-Service to partners' customers CONSUMERS 1. Additional treatment categories: Based on initial customer tests of new therapies in 2H 2024, we are expanding our treatment offerings and plan to migrate customers over time. Our treatment offerings are planned to be reviewed every quarter and we'll continue to evolve based on emerging science and therapies. The majority of emerging treatments will likely continue in the higher price range of these 2 categories. 2. Leverage unit economics to reinvest in scale: Longevity-as-a-service economics unlock potential profitability. Housecall costs are based on per-visit nurse hours, revenue is based on per-treatment prices. Labor & marketing costs are the same whether the treatment costs $300 or $30,000. Per-visit nurse hours (1 - 4 hours) don't vary with treatment, Labor & mktg costs fixed to nurse hours, not revenue. 1)Longevity and Anti-senescence Therapy Market 2)Stem Cell Therapy Cost (2024 update) The links provided are for informational purposes only. The presence of the links on this page does not imply endorsement by the respective websites and the accuracy or completeness of the information presented cannot be guaranteed. PARTNERS We are developing expertise in longevity delivery - in addition to our direct-to-consumer growth above, we also plan to provide plug-and-play in-home delivery to the customers of multiple types of longevity companies. We already have relationships established with several brands, including Inside Tracker and Function Health. We are aiming to capitalize on both the expansion of longevity clinics and the premium, high-demand nature of home-based advanced therapies (Source, Source).

FAQ